Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral…


Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025 Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025

See original here:
Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral...

Related Posts